• FDA approves Opdivo for initial treatment of advanced gastrointestinal cancers

    27 days ago - By Healio

    The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.
    The approval applies to use of the agent with certain types of chemotherapy as initial treatment for advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma.
    Nivolumab - a PD-1 inhibitor approved in the United States for treatment of several cancer types - is the first immunotherapy approved for first-line treatment of gastric cancer.
    An estimated 28,000 new cases of gastric cancer are diagnosed
    Read more ...

     

  • Overweight compounds likelihood of type 1 diabetes for children with high genetic risk

    Overweight compounds likelihood of type 1 diabetes for children with high genetic risk

    28 days ago - By Healio

    Children with a high genetic risk for developing type 1 diabetes are at an increased risk for the disease if they have overweight or obesity from age 2 to 10 years, according to trial data published in Diabetologia.
    “Previous studies have shown that increased rate of weight gain was associated with the development of type 1 diabetes,” Anita M. Nucci, PhD, RD, LD, chair and associate professor in the department of nutrition at Georgia State University, and Suvi M. Virtanen, MD, PhD, professor at the Finnish Institute for Health and Welfare and Tampere University, Finland, told
    Read more ...

     

  • Benefits of cell therapy for type 1 diabetes outweigh risks, FDA panel concludes

    Benefits of cell therapy for type 1 diabetes outweigh risks, FDA panel concludes

    28 days ago - By Healio

    An FDA advisory committee concluded that the investigational cell therapy donislecel demonstrated a favorable risk-benefit profile for certain patients with difficult-to-control type 1 diabetes.
    “There is nothing patients like more than freedom from dealing with the entire insulin issue,” Sandy Feng, MD, PhD, professor in residence with the department of surgery at University of California, San Francisco, and member of the Cellular, Tissue and Gene Therapies Advisory Committee, told the panel. “I do think this therapy can help some patients and will be
    Read more ...